Longevity Clinics in the United Kingdom

Private longevity clinics in the United Kingdom sell broad testing that the National Health Service (NHS) deliberately does not offer to adults without symptoms. The providers filling that gap are not one kind of business, and which kind you have walked into decides most of what you get.

Some are diagnostic imaging centres built around an expensive scanner, where a radiographer, the technician who runs the machine, produces images that a radiologist, the doctor who interprets them, reports on afterwards without ever meeting you. Others are doctor-led private general practices, several of them around London's Harley Street, which added preventive testing to an existing list of fee-paying patients.

At the far end sit single-service providers with one procedure and a nurse to deliver it, and direct-to-consumer testing companies that post you a kit or send you to a phlebotomist, the person who draws the blood. Whether a doctor ever reads your result is a question about the business, not about the test.

England places a statutory duty on local authorities to offer an NHS Health Check to eligible residents aged 40 to 74 once every five years, and it is a cardiovascular risk assessment rather than a broad search for disease: height, weight, waist, blood pressure, cholesterol, sometimes blood sugar, worked into a score for your chance of a heart or circulation problem over the next ten years. The people it leaves out are the ones already known to be at risk - anyone diagnosed with diabetes, hypertension, heart failure or stroke among other conditions, anyone prescribed statins, and anyone previously assessed at a twenty per cent or higher ten-year risk - on the logic that they belong under care rather than under screening.

Beyond it the adult screening list in England is short by design: cervical screening from 25 to 64, breast screening from 50 to 70, a bowel cancer home test kit every two years from 50 to 74, one ultrasound scan offered to men when they turn 65 for abdominal aortic aneurysm, a dangerous swelling of the body's main artery, and targeted lung screening for people aged 55 to 74 who have ever smoked.

What goes on that list is decided by the UK National Screening Committee (UK NSC), which advises ministers and the NHS in all four UK countries, and its refusals are the more instructive half of its work. It does not recommend population screening for prostate cancer, judging that harms including incontinence and erectile dysfunction in men who do not need treatment outweigh the benefit, and since its March 2026 review it has recommended prostate specific antigen (PSA) blood testing every two years only for men aged 45 to 61 who carry a pathogenic BRCA2 gene variant, an inherited change able to cause disease, together with a family history of breast, ovarian, pancreatic or prostate cancer. It does not recommend screening for ovarian cancer, because the large UK trial that tested it found screening did not reduce the number of women who died of the disease, nor for atrial fibrillation, an irregular heart rhythm, because it is not known whether screening does more good than the way cases are found and managed now.

Most of what a longevity clinic sells has an ordinary NHS route when there is a clinical reason for it, and the reason is the whole difference. A general practitioner can order blood tests, refer you for imaging when you have symptoms, and arrange cascade testing, which works outward from one diagnosed person to their blood relatives, where familial hypercholesterolaemia, an inherited form of very high cholesterol, is suspected; the National Institute for Health and Care Excellence (NICE) covers that in a dedicated guideline. The Royal College of Radiologists recommends body scanning only to investigate symptoms of disease and only under a doctor's direction, warning that scanning people without symptoms turns up irregularities that were never going to cause harm.

Longevity medicine is not a recognised speciality in the United Kingdom. The General Medical Council (GMC) keeps two statutory registers under the Medical Act 1983, the General Practitioner Register and the Specialist Register, the second built on holding a Certificate of Completion of Training in a recognised speciality, and no such certificate exists in longevity or age-management medicine, so the useful question is what a clinic's doctor is registered for instead.

Premises are regulated separately: in England a provider carrying on regulated activities such as diagnostic and screening procedures must register with the Care Quality Commission (CQC), and the exception for doctors treating patients in a surgery or consulting room does not extend to intravenous medicines or magnetic resonance imaging. Scotland, Wales and Northern Ireland run their own systems through Healthcare Improvement Scotland, Healthcare Inspectorate Wales and the Regulation and Quality Improvement Authority.

Testosterone and somatropin, a synthetic form of human growth hormone, are Class C controlled drugs under the Misuse of Drugs Act 1971 rather than ordinary prescription medicines. A marketing authorisation is the licence a medicine needs before it can be sold in the UK, and peptides and similar products that do not hold one reach patients, if at all, as unlicensed specials: supplied in response to an unsolicited order, made to a named prescriber's specification, for a patient in that prescriber's direct care. A condition of that exemption is that no advertisement for the product is published by anyone, so promoting an unlicensed injectable by name puts the supply outside it.

Cell and gene products are stricter again: the Medicines and Healthcare products Regulatory Agency (MHRA) classes them as advanced therapy medicinal products, which must go through clinical trials and hold a marketing authorisation before they can be placed on the UK market.

Private medical insurance in the UK is generally written to pay for treating conditions rather than for looking for them. Bupa's Select policy guide, for instance, carries an exclusion covering screening, monitoring and preventive treatment: no health checks or health screening, no routine tests or monitoring of medical conditions, and no tests or procedures carried out for screening or monitoring purposes. The same guide carries a cancer screening benefit as a separate item that applies only if your membership certificate shows it, which is the pattern to check in your own wording, though the working assumption should be that you are paying for this yourself.

The gap between two quoted prices is usually a gap in who reads the result rather than in what the machine measures. The laboratory work behind a blood panel is much the same test wherever the blood is drawn; what varies is whether a doctor sits down and explains it, whether the scan is reported by a radiologist who subspecialises in that part of the body, and whether the appointment after an ambiguous finding is included or billed again. Settle these in writing before you pay:

• the name and General Medical Council reference number of the clinician responsible for interpreting your results
• who pays for the further tests that a borderline finding triggers, and how quickly they can be arranged
• whether a copy of the full report, rather than a summary, goes to your own general practitioner

If you are travelling for this, and within Britain that usually means travelling to London, the appointment is the easy part. Paying privately does not move you along an NHS queue - Department of Health guidance for patients who want to buy additional private care restates the principle that access to NHS services is based on clinical need rather than ability to pay, requires any additional private care to be delivered separately from NHS care, and tells NHS organisations not to withdraw NHS care simply because someone has bought private care.

You have a right of access to a copy of your records from the clinic, and organisations normally have one month to respond. The Private Healthcare Information Network (PHIN), whose publication duties come from a Competition and Markets Authority order, publishes information on private consultants and hospitals, though it was built around inpatient and day-case procedures, so an outpatient testing service may not appear there at all.